This interspecies consistency not only reinforces the biological plausibility of TPPP3/COL10A1 as core fibrogenic effectors but also positions them as translatable biomarkers for stratifying NASH progression or evaluating antifibrotic therapies. This evidence concerns the gene TPPP3 and metabolic dysfunction-associated steatohepatitis.